Supp. Figure 1 MM-302 trastuzumab Vessels Hoechst Merge.

Slides:

Advertisements

Similar presentations

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Advertisements

Herceptin + 17-AAG Combination BT-474 Tumors

Supplemental Table 1 Source and authentication of cell lines.

The reading is 7.38 mm. The reading is 7.72 mm.

Biodistribution of 212Pb Conjugated Trastuzumab in Mice

Supplementary Figure 1. A B C MP-MRT-AN KP-MRT-NS KP-MRT-RY KP-MRT-YM

Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.

Daniel J. Lenihan et al. BTS 2016;1:

A Untreated mM maphos, 48h 20 mM maphos, 48h 50 mM maphos, 48hh B

Online Gifts Buy for wishes happy mother's day to yours choice and with happy gifts find here:

a b c d Supplemental Figure S x108 IFU 2x108 IFU 28 28

Median Tumor Development Time

Volume 21, Issue 2, Pages (February 2012)

Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells

Volume 3, Issue 6, Pages (June 2003)

Volume 29, Issue 1, Pages (January 2016)

Volume 130, Issue 7, Pages (June 2006)

Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression by Rosalba Salcedo, Maria Lourdes.

Molecular Therapy - Nucleic Acids

Brian Hutzen, Chun-Yu Chen, Pin-Yi Wang, Les Sprague, Hayley M

Volume 20, Issue 3, Pages (September 2011)

Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors

Volume 7, Issue 1, Pages (January 2005)

Volume 54, Issue 5, Pages (November 1998)

Molecular Therapy - Oncolytics

Volume 13, Issue 2, Pages (August 2000)

Volume 26, Issue 5, Pages e3 (November 2017)

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Treatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice Jörg.

Isoliquiritigenin Inhibits IL-1β-Induced Production of Matrix Metalloproteinase in Articular Chondrocytes Lei Zhang, Shiyun Ma, Hang Su, Jiaxiang Cheng

Visualizing Ligand Binding to a GPCR In Vivo Using NanoBRET

Nicholas D. James, Jim W. Growcott European Urology Supplements

Comparison of relative activity of Adjuplex and other commonly used adjuvants. Comparison of relative activity of Adjuplex and other commonly used adjuvants.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Volume 6, Issue 2, Pages (August 2004)

Stable and Potent Selenomab-Drug Conjugates

Anti-tumor effect of anti-PD-1 antibody against SCC3 tumor

Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines Wei Zhang, PhD, Michael.

Volume 20, Issue 3, Pages (September 2011)

Leto et al., Supplementary Figure S3

1. Identify the tissue.

C A B * * * * HCC1954 HCC1569 Supplementary-Figure S5 Tumor cells sc.

In vivo growth inhibition elicited by afatinib and GSK in a CLU–NRG1-rearranged PDX mouse model. In vivo growth inhibition elicited by afatinib.

Volume 26, Issue 5, Pages e3 (November 2017)

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

A: Chemical structure of pterosin A

Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth

Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.

Molecular Therapy - Oncolytics

A B Supplemental Figure 1. Growth of secondary (left-leg) tumors and lack of change in body weight in a Lewis lung carcinoma mouse model after treatments.

Tolerability of hRS7-CL2A-SN-38 in Swiss-Webster mice and Cynomolgus monkeys. Tolerability of hRS7-CL2A-SN-38 in Swiss-Webster mice and Cynomolgus monkeys.

coTCRcys-transduced T cells control tumor growth in vivo.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

THE GROWTH ENVIRONMENT.

CRA inhibits the growth of human tumor xenografts in vivo.

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

Whole-mount analysis of tumor induced lymphatic sprouting by confocal microscopy. Whole-mount analysis of tumor induced lymphatic sprouting by confocal.

Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.

SW620 xenografts treated with combination siKRAS+siPIK3CA/B.

MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.

PDL192 and inhibit the growth of xenograft tumors.

GCS-100 selectively kills KRAS-addicted lung tumors.

Transgenic mice with constitutively active NIK show increased tumor growth in bone. Transgenic mice with constitutively active NIK show increased tumor.

CPI-444 synergizes with anti–PD-L1 and anti–CTLA-4 treatment.

Molecular Therapy - Nucleic Acids

Fig. 5 DDO-5936 dose-dependently impairs the growth of xenografted HCT116 cells in nude mice. DDO-5936 dose-dependently impairs the growth of xenografted.

Supplementary Figure 1: AGS-22M6E ADC specific localization in tumor xenografts. AG-B1 tumor pieces were implanted in ICR-SCID mice subcutaneously.

Presentation transcript:

Supp. Figure 1 MM-302 trastuzumab Vessels Hoechst Merge

* p = 0.0189 * p = 0.0101 Supp. Figure 2 16 12 Percent injected dox/gram tissue MM-302 + IgG MM-302 + T-DM1 PBS trastuzumab alone 16 12 4 * p = 0.0189 8 * p = 0.0101

time following injection (hrs) Supp. Figure 3 MM-302 (3 mg/kg) MM-302 + trastuzumab ng dox/5mL plasma (log) time following injection (hrs)

Supp. Figure 4 BT474-M3 NCI-N87 MM-302 + trast. Bliss additive value MM-302 alone trastuzumab alone Time following first dose (days) BT474-M3 NCI-N87 % tumor growth inhibition 100 80 60 40 20 5 10 15 25 30 35